| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8827467 | Transplantation Proceedings | 2017 | 5 Pages |
Abstract
Consistent with previous data, a high incidence of infections was observed after rituximab treatment in kidney transplant recipients. Most infections occurred within 6 months after rituximab initiation. With more than 3 years of follow-up, we were able to document a low incidence of secondary malignancies after rituximab with only 1 case in our cohort.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
E. Schrezenmeier, K. Budde, O. Staeck, L. Lehner, M. Duerr, D. Khadzhynov, T. Dörner, F. Halleck,